Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

Table 6 Relationship between clinical characteristics and OS/DFS in patients with undetectable or low baseline HBV DNA levels (<2000 IU/mL), as determined by univariate and multivariate Cox regression analysis

Variable	OS				DFS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR	P value	HR (95 % CI)	P value	HR	P value	HR (95 % CI)	P value
Age (≥50 vs. <50 years)	1.173	0.566			0.750	0.183
Gender (female vs. male)	0.819	0.645			0.963	0.902
HBeAg (positive vs. negative)	1.321	0.554			1.407	0.330
Tumor size (≥5 or <5 cm)	2.013	0.013	Not significant		1.772	0.006	1.997 (1.295–3.044)	0.002
Tumor number (multiple vs. single)	2.612	0.013	Not significant		2.194	0.015	2.761 (1.440–5.296)	0.002
Pathologic grades (IV/III/II/I)	1.535	0.073	Not significant		1.346	0.100	Not significant
Microvascular thrombus (yes vs. no)	1.902	0.140			1.561	0.205
Tumor capsule (without/incomplete/complete)	1.046	0.784			0.873	0.284
AFP (>25 vs. ≤25 ng/mL)	1.084	0.777			1.230	0.345
ALT (>40 vs. ≤40 IU/L)	1.219	0.487			1.115	0.618
AST (>45 vs. ≤45 IU/L)	0.820	0.626			1.107	0.712
ALB (≥35 vs. <35 g/L)	0.490	0.324			0.712	0.562
TBIL (>20.5 vs. ≤20.5 μmol/L)	1.167	0.661			1.439	0.158
Prothrombin time (>13.5 vs. ≤13.5 s)	1.296	0.432			1.272	0.342
Antiviral treatment (yes vs. no)	0.641	0.206			1.068	0.777
Recurrence (yes vs. no)	5.859	<0.001	5.859 (3.007–11.416)	<0.001

OS overall survival, DFS disease-free survival, CI confidence interval, HR hazard ratio, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB serum albumin, TBIL serum total bilirubin

ISSN: 2523-3548